AGIOS PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 |
| Cost of revenue | $6.3M | $4.2M | $2.9M | $1.7M | $0 |
| Selling, general & administrative | $180.3M | $156.8M | $119.9M | $121.7M | $121.4M |
| Research and development | $339.5M | $301.3M | $295.5M | $279.9M | $257.0M |
| Operating income | -$472.1M | -$425.7M | -$391.5M | -$389.0M | -$378.4M |
| Pretax income | -$413.8M | $718.0M | -$352.1M | -$231.8M | -$356.5M |
| Income tax expense | -$1.0M | $44.2M | $0 | $0 | — |
| Net income | -$412.8M | $673.7M | -$352.1M | -$231.8M | $1.6B |
| Balance Sheet | |||||
| Cash and equivalents | $89.1M | $76.2M | $88.2M | $139.3M | $203.1M |
| Current assets | $942.1M | $965.6M | $833.8M | $832.8M | $1.1B |
| Total assets | $1.3B | $1.7B | $937.1M | $1.2B | $1.4B |
| Current liabilities | $82.2M | $81.2M | $68.0M | $62.6M | $59.8M |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M |
| Stockholders' equity | $1.2B | $1.5B | $811.0M | $1.1B | $1.3B |
| Cash Flow Statement | |||||
| Cash from operations | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M |
| Depreciation and amortization | $5.2M | $5.7M | $6.6M | $8.4M | $8.8M |
| Stock-based compensation | $52.6M | $42.8M | $44.8M | $49.3M | $53.5M |
| Capital expenditure | $4.3M | $1.7M | $999,000 | $4.9M | $5.7M |
| Free cash flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M |
| Share repurchases | — | — | $0 | $0 | $802.5M |
Shares outstanding 59.5M · Free float 87.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.